# Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

> clinical trial · VERIFIED · 2026-07-06

Status: NOT_YET_RECRUITING · Sponsor: Henan Cancer Hospital · Condition: Mantle Cell Lymphoma (MCL)

- Company: Henan Cancer Hospital
- Sector: Mantle Cell Lymphoma (MCL)
- Primary source: https://clinicaltrials.gov/study/NCT07684950

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.